Prostate cancer Board decisions

The Board has granted service connection for Barrett's esophagus, sick sinus syndrome, and prostate cancer due to exposure at Camp Lejeune. The Veteran also receives special monthly compensation based on the loss of use of a creative organ.

The Board has granted a 60 percent disability rating for the Veteran's residuals of prostate cancer, effective April 1, 2025. The reduction from 100 percent to 40 percent was proper as the cancer was in remission and no longer active.

The Veteran's earlier effective date for the award of service connection for psychiatric disability, prostate cancer, and hypertension is granted. Effective dates are assigned for SMC at the housebound rate from March 20, 2025.

The Veteran's claims for service connection for colon cancer at appendix stump, carcinoid cancer of the liver, and prostate cancer are being remanded due to duty-to-assist errors. The Board will obtain additional records and medical opinions as needed.

The Board has remanded the Veteran's claims due to errors in obtaining relevant medical records and potential TERA development. The Veteran is also asked to provide additional information regarding his hypertension.

The Board has decided that the claim of service connection for prostate cancer should be remanded due to a lack of an opinion regarding the etiology of the condition.

The Board has remanded the claims of accrued benefits for prostate cancer, Alzheimer's disease (dementia), and hypertension due to pre-decisional duty to assist errors. The AOJ is required to develop the record with an ILER, TERA memorandum, and VA medical opinions regarding toxic risk exposure activities and potential service connection.,The Board has also remanded the claim for service connection for the cause of the Veteran's death due to inextricably intertwined issues with the claims for accrued benefits. The AOJ is required to develop the record and provide an addendum opinion on the nature and etiology of the Veteran's dementia, prostate cancer, and hypertension.

The Board has remanded the claims of accrued benefits for prostate cancer, Alzheimer's disease (dementia), and hypertension due to pre-decisional duty to assist errors. The AOJ is required to develop the record with an ILER, TERA memorandum, and VA medical opinions regarding toxic risk exposure activities and potential service connection.,The Board has also remanded the claim for service connection for the cause of the Veteran's death due to inextricably intertwined issues with the claims for accrued benefits. The AOJ is required to develop the record and provide an addendum opinion on the nature and etiology of the Veteran's dementia, prostate cancer, and hypertension.

The Veteran's appeal of a disability rating reduction for prostate cancer (currently rated at 100 percent) is dismissed because no adjudication reducing or discontinuing the rating has occurred.

The Board has determined that the Veteran's erectile dysfunction is not due to VA treatment for prostate cancer, and thus does not meet the criteria for compensation under 38 U.S.C. § 1151.

The Veteran's prostate cancer with voiding dysfunction and urinary incontinence is rated at 60 percent from March 17, 2025. The Board found that the evidence supported a higher rating due to more frequent use of absorbent materials. Service connection for an acquired psychiatric disability (including anxiety, depression, and insomnia) was denied as there is no persuasive evidence of such conditions during or recent to the pendency of the claim.

The Veteran's prostate cancer residuals, including urinary hesitancy and retention, are granted with a December 13, 2019 effective date. The Veteran is also granted an initial 50 percent rating for major depressive disorder from May 3, 2019, but no earlier. Other claims were denied.

The Veteran's prostate cancer is granted as service connected due to exposure to herbicides in Vietnam.

The Veteran's claim for service connection for diabetes mellitus, type 2 is denied as there is no valid diagnosis of the condition.,The Veteran's claim for a rating in excess of 30 percent for coronary artery disease (CAD) is denied due to lack of evidence showing heart failure symptoms at a workload of 3.1-5.0 METs.

The Board denied the Veteran's claims for an earlier effective date for prostate cancer residuals and service connection for obstructive sleep apnea as secondary to PTSD and tinnitus, finding that the evidence did not support these claims.

The Veteran's claims for service connection have been dismissed due to his death while the appeal was pending.

The Board has granted the Veteran's claim for service connection for prostate cancer, finding that his exposure to PFAS at Richards-Gebaur Air Force Base during military service is related to his current condition.

The Veteran's prostate cancer is granted on a direct basis as it is presumed to be related to his service, including his service in the Persian Gulf region. The Board found that environmental exposure factors were significant in determining the cause of the prostate cancer.

The Veteran's TDIU claim has been granted, and the Board is remanding the earlier effective date for DEA based on his TDIU award.

The Board dismissed the appeals of service connection for glaucoma and prostate cancer as untimely, due to the Veteran not submitting a timely Notice of Disagreement within one year from the March 2024 rating decision.